Hello everyone!
I'm about to start a pilot study concerning some pretty aged mice (18-21 months) looking into survival rates with tamoxifen IP injections, where it can have some nasty effects on the mice. I've seen many papers using 5 doses in consecutive days, and a few with 3 doses; 3 would be easier on the mice but I also want to ensure efficient recombination which most people are using the 5 days for. We are using PDGFRα-CreERT2 mice as well.
Does anyone have any insight to why they may select 5 days of injections compared to 3 days?
Thank you,
Sarah